← Russell 3000 cross-section

MGTX MeiraGTx Holdings plc

Trailing twelve months to 2025-09-30 · as filed 2026-05-14, not restated
Healthcare

Scale

Market cap
$1.4bn
Revenue TTM
$27m
Net income TTM
$-169m
Free cash flow
$-121m
Composite score
Sector rank
#1847

Valuation

P / E
EV / EBITDA
EV / sales
49.5
FCF yield
-8.82%
Earnings yield vs 10-yr
-17.02pp

Earnings yield vs 10-yr compares what the business earns per pound invested against the 4.73% a 10-year US Treasury note pays for no equity risk. Negative means you are paying up front for growth not yet delivered.

Quality and growth

Net margin
-615.3%
EBITDA margin
-552.3%
ROE
415.9%
ROIC
Revenue growth
96.8%

Insider activity, last 90 days

Net open-market
$-1.97m
Buyers
0
Sellers
3

Open-market purchases and sales only. Grants, option exercises, gifts and shares withheld for tax are excluded: they are how people are paid, not what they think.

What management said

To date, we have financed our operations primarily with cash on hand and proceeds from the sales of our equity securities, debt financings, strategic collaborations and asset sales, including (i) upfront and milestone payments in connection with the Collaboration, Option and License Agreement with Janssen Pharmaceuticals, Inc. Our net income for the three-month period ended June 30, 2026 and net loss for the three-month period ended June 30, 2025 were $160.7 million and $38.8 million, respectively. Our net income for the six-month period ended June 30, 2026 and net loss for the six-month period ended June 30, 2025 were $114.4 million and $78.8 million, respectively. …MeiraGTx Holdings plc, 10-Q, period ended 2026-06-30, filed 2026-08-13

Read the full passage →